查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1990249

Fentanyl市場：2026-2032年全球市場按產品類型、給藥途徑、應用和分銷管道分類的預測

Fentanyl Market by Product Type, Route of Administration, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，Fentanyl市場價值將達到 24.7 億美元，到 2026 年將成長到 25.9 億美元，到 2032 年將達到 34.4 億美元，複合年成長率為 4.81%。

主要市場統計數據
基準年 2025 24.7億美元
預計年份：2026年 25.9億美元
預測年份 2032 34.4億美元
複合年成長率 (%) 4.81%

對Fentanyl在現代醫學中的雙重作用以及影響其臨床應用獲取和管理的公共衛生要求進行清晰的背景概述。

Fentanyl目前的處境錯綜複雜，既有臨床需求，也有公共衛生緊迫性。合成鴉片類藥物在麻醉、急性疼痛管理和安寧療護中發揮著至關重要的作用，同時也是減少鴉片類藥物相關危害的關鍵所在。因此，從醫院處方集和藥物研發團隊到監管機構和減害組織，所有利益相關人員都面臨著相互衝突的挑戰：既要確保臨床用藥的合理性，又要限制藥物的濫用和誤用，還要適應不斷變化的供應鏈和監管壓力。

管理方法的創新、監管的加強以及供應鏈的韌性正在重新定義臨床實踐和商業策略。

由於製劑創新、監管趨嚴以及供應鏈重組，Fentanyl市場正經歷變革性的轉變。諸如更精準的經皮基質和專為緊急情況設計的鼻內給藥系統等新型給藥技術，在拓展臨床應用的同時，也對合理用藥管理和監測提出了新的要求。同時，監管環境也日益精細化，監管機構加強了對處方行為、通路和上市後監測機制的監管。

2025 年美國的關稅環境以及由此產生的策略採購因應措施正在重塑整個價值鏈的供應連續性和監管合規性。

美國將於2025年加徵關稅，這進一步增加了Fentanyl合法生產和分銷企業的營運複雜性。關稅帶來的成本壓力迫使製造商重新評估其原料藥和關鍵生產材料的採購地點和供應商關係。為此，採購團隊正在尋求供應商多元化，並探索近岸外包方案，以降低關稅波動帶來的風險，同時確保醫院和藥房關鍵物資的持續供應。

一個複雜的細分框架，將產品配方、給藥途徑、臨床應用和分銷實際情況與策略重點連結起來。

細分市場分析揭示了不同產品類型、給藥途徑、臨床應用和分銷管道的需求因素各不相同，這些因素對臨床實踐、法律規範和商業規劃均有獨特的影響。根據產品類型，市場參與企業必須滿足每種產品的特定臨床和生產要求，例如注射劑、錠劑/片劑、鼻噴霧和貼片。注射劑的無菌生產和低溫運輸要求與錠劑和片劑的製劑穩定性和濫用預防設計挑戰形成鮮明對比。另一方面，鼻噴霧和貼片各自具有獨特的給藥動力學和使用者介面因素，這些因素會影響患者的治療效果和潛在的濫用風險。

美洲、歐洲、中東和非洲以及亞太地區的不同區域管理體制、供應基礎設施和臨床重點如何決定策略的實施和進入途徑？

區域趨勢對臨床實踐模式、法律規範和供應鏈結構起著決定性作用，美洲、歐洲、中東、非洲和亞太地區的營運和政策環境各不相同。在美洲，醫療保健系統高度重視急診注射的可近性和減少傷害的政策，這導致門診藥品配發受到更嚴格的監管，同時也集中了對速效注射劑和緊急鼻噴劑的需求。該地區的監管機構越來越注重在滿足臨床需求和加強處方管控之間取得平衡，相關人員必須積極參與公共衛生舉措，以確保充足的治療藥物供應。

以安全生產、差異化給藥技術和符合監管規定的商業化為優先的競爭策略和協作能力。

該行業的參與企業涵蓋範圍廣泛，從專業的藥物研發公司到大規模綜合生產企業和合約研發生產機構（CDMO），每家公司在製劑科學、藥品合規性和商業化方面都擁有不同的能力。領先的臨床研發公司正在投資於濫用預防技術和以使用者為中心的劑量設計，以滿足臨床醫生對更可預測的療效和安全性的期望。契約製造生產商正在擴大其安全生產能力，並加強其品管體系，以處理無菌注射劑和複雜的經皮吸收基質。同時，經銷商正在加強其可追溯性和儲存歷史管理實踐，以應對監管機構和支付方的審查。

為臨床開發人員和供應鏈管理人員提供關鍵建議，以確保患者獲得治療、管理監管風險並建立具有韌性的業務結構。

產業領導者必須採取多管齊下的方法來應對Fentanyl市場的複雜局面，整合臨床證據的產生、供應鏈的韌性以及積極的監管合作。首先，投資應優先考慮能夠提高病人安全性和支持藥物管理目標的製劑。這包括具備防濫用特性和劑量設計，以最大限度地降低藥物濫用風險，同時保持臨床療效。臨床開發項目應與真實世界證據研究保持一致，證明芬太尼在麻醉、疼痛管理和安寧療護領域的治療價值，從而促進醫療機構的知情處方和應用。

採用穩健的、基於三角測量的研究方法，將對臨床醫生和供應鏈相關人員的初步訪談與全面的二手證據和專家檢驗相結合。

本分析的調查方法採用三角測量法，結合了對主要相關人員的訪談、有針對性的二手資訊的整合以及跨部門檢驗，從而確保研究的深度和可靠性。主要研究對象包括麻醉、疼痛管理和安寧療護領域的臨床醫生、醫院系統的採購和物流經理、法規事務專家以及具有管制藥品處理經驗的生產主管。這些相關人員的意見有助於識別營運挑戰、推廣障礙以及製劑開發的優先事項。

將臨床、營運和監管重點相結合，凸顯了整合策略以保護患者照護和供應連續性的必要性。

總之，Fentanyl目前的現狀需要在重要的臨床效益與日益複雜的營運和監管之間尋求微妙的平衡。劑量和製劑的創新為改善病患療效提供了重要契機，但必須同時加強生產安全、與監管機構積極合作，並採取有針對性的合理用藥措施。貿易政策趨勢和區域監管差異進一步加劇了供應連續性和取得途徑的複雜性，凸顯了靈活的籌資策略和跨部門合作的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章Fentanyl市場：依產品類型分類

  • 注射藥物
  • 錠劑/片劑
  • 鼻噴霧
  • 修補

第9章Fentanyl市場：依給藥途徑分類

  • 口服
  • 腸外
  • 經皮

第10章：Fentanyl市場：依應用領域分類

  • 醫療用途
    • 麻醉
    • 疼痛管理
    • 安寧療護
  • 研究與開發

第11章Fentanyl市場：按分銷管道分類

  • 醫院藥房
  • 零售藥房

第12章Fentanyl市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章Fentanyl市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章Fentanyl市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國Fentanyl市場

第16章：中國Fentanyl市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alvogen
  • Apotex Inc.
  • Biesterfeld SE
  • Daiichi Sankyo Company, Limited
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC
  • Humanwell Healthcare（Group）Co., Ltd.
  • Kyowa Hakko Kirin Co. Ltd.
  • Mallinckrodt plc
  • Nutriband Inc.
  • Pfizer Inc.
  • Piramal Pharma Limited
  • QuVa Pharma, Inc
  • SCA Pharma
  • Spectrum Chemical Mfg. Corp.
  • Terumo Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Tofigh Daru Research & Engineering Company
  • Verve HumanCare Laboratories
  • Viatris Inc.
Product Code: MRR-CB04E056533E

The Fentanyl Market was valued at USD 2.47 billion in 2025 and is projected to grow to USD 2.59 billion in 2026, with a CAGR of 4.81%, reaching USD 3.44 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.47 billion
Estimated Year [2026] USD 2.59 billion
Forecast Year [2032] USD 3.44 billion
CAGR (%) 4.81%

A clear contextual overview of fentanyl's dual role in modern medicine and the public health imperative shaping clinical access and control

The fentanyl landscape occupies a complex intersection of clinical necessity and public health urgency. Synthetic opioids serve indispensable roles in anesthesia, acute pain management, and palliative care, while simultaneously being central to broader efforts to reduce opioid-related harm. As a result, stakeholders from hospital formularies and pharma development teams to regulators and harm-reduction organizations face competing imperatives: preserve appropriate clinical access, limit diversion and misuse, and adapt to shifting supply chain and regulatory pressures.

Over recent years, technological advances in formulation and delivery, combined with intensified law enforcement and public health interventions, have reshaped how fentanyl is manufactured, distributed, and used. At the same time, legitimate clinical demand continues to drive innovation in transdermal systems, nasal spray options for emergency use, and rapidly acting injectables for controlled settings. Consequently, the sector demands nuanced strategies that reconcile therapeutic benefit with tighter controls and heightened public scrutiny.

This introduction establishes the context for a comprehensive exploration of market dynamics, regulatory influences, and operational considerations. It frames the subsequent analysis so that clinical leaders, supply chain managers, and policy teams can assess risk, prioritize investments, and design interventions that maintain patient care standards while mitigating externalities such as diversion and illicit manufacture.

How innovation in delivery, regulatory tightening, and supply chain resilience are jointly redefining clinical practice and commercial strategy

The fentanyl landscape is undergoing transformative shifts driven by innovation in formulations, regulatory tightening, and a reconfiguration of supply chains. Novel delivery technologies, including more precise transdermal matrices and intranasal systems designed for emergency administration, are widening clinical options while also raising new stewardship and monitoring requirements. Concurrently, regulatory frameworks are becoming more granular, with authorities increasing scrutiny of prescribing practices, distribution channel controls, and post-market surveillance mechanisms.

Supply chain resilience has emerged as a critical axis of change. Manufacturers and distributors are reevaluating sourcing strategies for active pharmaceutical ingredients, implementing enhanced traceability protocols, and investing in manufacturing security to reduce vulnerability to diversion. At the same time, research and development priorities are shifting toward formulations that balance rapid onset with abuse-deterrent features, creating pressure for cross-functional collaboration between formulation scientists, clinical teams, and compliance officers.

Taken together, these shifts require organizations to adapt their operating models, aligning clinical development, procurement, and regulatory affairs under a unified risk-management framework. The evolving landscape also amplifies the role of stakeholder engagement, as collaboration with payers, providers, and public health agencies becomes essential to deploying therapeutic options responsibly and effectively.

The 2025 U.S. tariff environment and resultant strategic procurement responses reshaping supply continuity and regulatory compliance across the value chain

United States tariffs instituted in 2025 introduced an additional layer of operational complexity for companies involved in legitimate fentanyl production and distribution. Tariff-related cost pressures have prompted manufacturers to reassess sourcing geographies and supplier relationships for active pharmaceutical ingredients and key manufacturing inputs. In response, procurement teams have initiated supplier diversification efforts and explored nearshoring options to mitigate exposure to tariff volatility while preserving continuity for critical hospital and pharmacy supplies.

These trade policy changes have also accelerated conversations around supply chain transparency and vertical integration. Organizations are prioritizing investments in serialization, enhanced supplier audits, and contractual mechanisms that allocate tariff risk across the value chain. At the same time, regulatory compliance functions are tracking how import/export documentation and controlled-substance regulations interplay with tariff classifications to avoid inadvertent disruptions at customs clearance points.

Clinicians and hospital administrators are watching procurement implications carefully, as changes in supplier relationships can affect lead times and formulation availability. Accordingly, cross-functional teams are required to model scenario responses that preserve therapeutic access, especially for anesthesia and palliative care settings where continuity is paramount. The tariff environment has therefore reinforced the need for adaptable procurement strategies, robust supply monitoring, and proactive engagement with trade counsel to navigate regulatory and fiscal requirements effectively.

A nuanced segmentation framework linking product formulation, administration pathways, clinical application, and distribution realities to strategic priorities

Segmentation analysis reveals differentiated demand drivers across product types, administration routes, clinical applications, and distribution channels, each of which carries distinct implications for clinical practice, regulatory oversight, and commercial planning. Based on Product Type, market participants must navigate the unique clinical and manufacturing requirements of Injectables, Lozenges & Tablets, Nasal Sprays, and Patches; the sterile manufacturing and cold-chain considerations for injectables contrast sharply with the formulation stability and abuse-deterrent design challenges for lozenges and tablets, while nasal sprays and patches each introduce unique delivery kinetics and user-interface factors that affect both patient outcomes and misuse potential.

Based on Route of Administration, the clinical pathways differ significantly between Oral, Parenteral, and Transdermal approaches; parenteral administration remains essential for operating-room anesthesia and acute inpatient pain control, oral routes are predominant for controlled outpatient dosing and short-term pain management, and transdermal systems provide sustained release options particularly relevant to palliative care and chronic pain under close supervision. Based on Application, stakeholders must balance requirements for Medical Use and Research & Development, where Medical Use further subdivides into Anesthesia, Pain Management, and Palliative Care; each application imposes distinct evidence needs, prescribing patterns, and stewardship priorities, with anesthesia demanding predictable rapid onset, pain management requiring titratable dosing strategies, and palliative care emphasizing prolonged, comfortable symptom relief.

Based on Distribution Channel, hospitals pharmacies and retail pharmacies present contrasting operational realities; hospital pharmacies handle complex inpatient regimens and controlled administration environments while retail pharmacies must manage dispensing controls, patient counseling, and outpatient adherence challenges. Integrating these segmentation lenses enables clinical development teams and supply chain leaders to target product design, risk mitigation, and distribution policies with precision, thereby aligning regulatory engagement, commercial approaches, and stewardship programs to each segment's specific requirements.

How distinct regional regulatory regimes, supply infrastructures, and clinical priorities across the Americas, EMEA, and Asia-Pacific determine strategic execution and access pathways

Regional dynamics play a decisive role in clinical practice patterns, regulatory frameworks, and supply chain architectures, with distinct operational and policy environments across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, healthcare systems exhibit a strong emphasis on both acute care access and harm-reduction policies, leading to concentrated demand for rapid-onset injectables and emergency nasal formulations alongside intensified monitoring of outpatient dispensing. Regulatory agencies in the region are increasingly focused on balancing clinical need with tighter prescribing controls, and stakeholders must engage proactively with public health initiatives to maintain appropriate therapeutic availability.

In Europe, Middle East & Africa, regulatory heterogeneity and varying levels of infrastructure maturity shape adoption pathways for advanced delivery systems. Some European markets prioritize stringent pharmacovigilance and tighter preauthorization procedures, while healthcare delivery models across the Middle East and Africa may prioritize supply chain robustness and capacity-building to ensure consistent access in hospital settings. These regional distinctions affect how manufacturers approach clinical evidence generation and market access strategies.

The Asia-Pacific region presents a mix of rapidly evolving regulatory frameworks, manufacturing capability expansion, and significant patient populations with unmet pain management needs. Investments in local production capacity and distribution networks are expanding, with incremental adoption of transdermal and nasal emergency formulations. Across regions, successful strategies require tailored regulatory engagement, adaptive supply planning, and culturally informed clinical education to ensure safe and effective therapeutic use while responding to local public health priorities.

Competitive strategies and collaborative capabilities that prioritize secure manufacturing, differentiated delivery technologies, and regulatory-aligned commercialization

Industry participants range from specialized pharmaceutical developers to large integrated manufacturers and contract development and manufacturing organizations, each bringing different capabilities in formulation science, controlled-substance compliance, and commercialization. Leading clinical developers are investing in abuse-deterrent technologies and user-centric delivery designs to meet clinician expectations for predictable efficacy and improved safety profiles. Contract manufacturers are expanding secure production capacities and bolstering quality systems to support sterile injectables and complex transdermal matrices, while distributors are enhancing traceability and chain-of-custody practices to address regulatory and payer scrutiny.

Across the competitive landscape, collaboration between developers, manufacturers, and healthcare institutions is increasingly important. Strategic partnerships enable accelerated clinical validation and distribution scale-up, while alliances with academic centers and clinical networks support evidence generation in specialized applications such as anesthesia protocols and palliative care regimens. Concurrently, firms with deep regulatory expertise are securing advantages by shaping labeling, risk mitigation strategies, and post-market surveillance frameworks that meet evolving expectations from authorities.

Taken together, company strategies are coalescing around secure manufacturing, differentiated delivery technologies, and integrated compliance solutions. Organizations that can combine scientific rigor with operational security and stakeholder engagement will be best positioned to address both clinical demand and regulatory obligations.

High-impact recommendations for clinical developers and supply chain leaders to secure patient access, manage regulatory risk, and build resilient operations

Industry leaders must adopt a multi-pronged approach that integrates clinical evidence generation, supply chain resilience, and proactive regulatory engagement to navigate the complex fentanyl landscape. First, prioritize formulation investments that enhance patient safety and support stewardship objectives, including abuse-deterrent properties and delivery designs that minimize diversion risk while maintaining clinical efficacy. Align clinical development programs with real-world evidence initiatives to demonstrate therapeutic value across anesthesia, pain management, and palliative care contexts, thereby facilitating informed prescribing and institutional adoption.

Second, strengthen supply chain transparency and supplier diversification to reduce exposure to trade policy shifts and other disruptions. Implement serialization, enhanced traceability, and contractual risk-sharing mechanisms, while exploring nearshoring opportunities for critical intermediates and finished goods. Third, engage early and consistently with regulators and payers to co-develop pragmatic access pathways and post-market monitoring strategies that address safety concerns without undermining legitimate clinical use. Finally, invest in stakeholder education and cross-sector partnerships with hospitals, pharmacies, and public health organizations to build trust and operational readiness for new formulations and stewardship programs.

By executing these actions in combination, organizations can protect patient access, reduce systemic risk, and create defensible competitive positions based on safety, reliability, and clinical alignment.

A robust, triangulated research approach combining primary clinician and supply chain interviews with comprehensive secondary evidence and expert validation

The research methodology underpinning this analysis integrates a triangulated approach combining primary stakeholder interviews, targeted secondary source synthesis, and cross-functional validation to ensure both depth and reliability. Primary engagement included consultations with clinicians across anesthesia, pain management, and palliative care, procurement and logistics leaders in hospital systems, regulatory affairs specialists, and manufacturing executives with controlled-substance experience. These stakeholder inputs informed the identification of operational pain points, adoption barriers, and formulation priorities.

Secondary analysis leveraged peer-reviewed clinical literature, regulatory guidance documents, and public health surveillance reports to contextualize clinical needs and policy trajectories. In addition, supply chain documentation and trade policy records were examined to map sourcing risks and tariff implications. Data synthesis employed thematic coding to identify recurrent trends and to align strategic implications with observable operational shifts. Finally, findings were validated through iterative reviews with subject matter experts to ensure accuracy and practical relevance for decision-makers across development, procurement, and regulatory functions.

Synthesis of clinical, operational, and regulatory priorities highlighting the imperative for integrated strategies that protect patient care and supply continuity

In conclusion, the fentanyl landscape presents an intricate balance between indispensable clinical benefits and escalating operational and regulatory complexity. Innovations in delivery and formulation offer meaningful opportunities to improve patient outcomes, but they must be accompanied by strengthened manufacturing security, proactive regulatory engagement, and targeted stewardship efforts. Trade policy developments and regional regulatory variation further complicate supply continuity and access pathways, underscoring the importance of adaptable procurement strategies and cross-functional coordination.

Organizations that align clinical development with real-world evidence generation, invest in secure and traceable supply chains, and engage constructively with regulators and health system stakeholders will be best positioned to navigate these challenges. Ultimately, success requires an integrated response that protects patient care, mitigates risks of diversion, and supports sustainable operational models in a dynamic global environment. This report provides the actionable intelligence needed to inform those strategic decisions and to drive responsible, patient-centered clinical access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Fentanyl Market, by Product Type

  • 8.1. Injectables
  • 8.2. Lozenges & Tablets
  • 8.3. Nasal Sprays
  • 8.4. Patches

9. Fentanyl Market, by Route of Administration

  • 9.1. Oral
  • 9.2. Parenteral
  • 9.3. Transdermal

10. Fentanyl Market, by Application

  • 10.1. Medical Use
    • 10.1.1. Anesthesia
    • 10.1.2. Pain Management
    • 10.1.3. Palliative Care
  • 10.2. Research & Development

11. Fentanyl Market, by Distribution Channel

  • 11.1. Hospitals Pharmacies
  • 11.2. Retail Pharmacies

12. Fentanyl Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Fentanyl Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Fentanyl Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Fentanyl Market

16. China Fentanyl Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alvogen
  • 17.6. Apotex Inc.
  • 17.7. Biesterfeld SE
  • 17.8. Daiichi Sankyo Company, Limited
  • 17.9. Fresenius SE & Co. KGaA
  • 17.10. Hikma Pharmaceuticals PLC
  • 17.11. Humanwell Healthcare (Group) Co., Ltd.
  • 17.12. Kyowa Hakko Kirin Co. Ltd.
  • 17.13. Mallinckrodt plc
  • 17.14. Nutriband Inc.
  • 17.15. Pfizer Inc.
  • 17.16. Piramal Pharma Limited
  • 17.17. QuVa Pharma, Inc
  • 17.18. SCA Pharma
  • 17.19. Spectrum Chemical Mfg. Corp.
  • 17.20. Terumo Corporation
  • 17.21. Teva Pharmaceutical Industries Ltd.
  • 17.22. Tofigh Daru Research & Engineering Company
  • 17.23. Verve HumanCare Laboratories
  • 17.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FENTANYL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FENTANYL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FENTANYL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FENTANYL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FENTANYL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FENTANYL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FENTANYL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES FENTANYL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA FENTANYL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FENTANYL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FENTANYL MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FENTANYL MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FENTANYL MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FENTANYL MARKET SIZE, BY LOZENGES & TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FENTANYL MARKET SIZE, BY LOZENGES & TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FENTANYL MARKET SIZE, BY LOZENGES & TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FENTANYL MARKET SIZE, BY NASAL SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FENTANYL MARKET SIZE, BY NASAL SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FENTANYL MARKET SIZE, BY NASAL SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FENTANYL MARKET SIZE, BY PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FENTANYL MARKET SIZE, BY PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FENTANYL MARKET SIZE, BY PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FENTANYL MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FENTANYL MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FENTANYL MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FENTANYL MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FENTANYL MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FENTANYL MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FENTANYL MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FENTANYL MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FENTANYL MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FENTANYL MARKET SIZE, BY MEDICAL USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FENTANYL MARKET SIZE, BY MEDICAL USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FENTANYL MARKET SIZE, BY MEDICAL USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FENTANYL MARKET SIZE, BY ANESTHESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FENTANYL MARKET SIZE, BY ANESTHESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FENTANYL MARKET SIZE, BY ANESTHESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FENTANYL MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FENTANYL MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FENTANYL MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FENTANYL MARKET SIZE, BY PALLIATIVE CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FENTANYL MARKET SIZE, BY PALLIATIVE CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FENTANYL MARKET SIZE, BY PALLIATIVE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FENTANYL MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FENTANYL MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FENTANYL MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FENTANYL MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FENTANYL MARKET SIZE, BY HOSPITALS PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FENTANYL MARKET SIZE, BY HOSPITALS PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FENTANYL MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FENTANYL MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FENTANYL MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FENTANYL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS FENTANYL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA FENTANYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA FENTANYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA FENTANYL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE FENTANYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST FENTANYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA FENTANYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC FENTANYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL FENTANYL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN FENTANYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. GCC FENTANYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. GCC FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. GCC FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION FENTANYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS FENTANYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. G7 FENTANYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. G7 FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. G7 FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. NATO FENTANYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. NATO FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. NATO FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL FENTANYL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES FENTANYL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA FENTANYL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA FENTANYL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA FENTANYL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA FENTANYL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA FENTANYL MARKET SIZE, BY MEDICAL USE, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA FENTANYL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)